Company Overview

Pacific Biosciences of California, Inc. is a life sciences technology company focused on the development and commercialization of advanced DNA sequencing systems. The company operates primarily within the genomics and biotechnology research industries, providing sequencing platforms that enable highly accurate and long-read DNA analysis. Its core technologies are used by academic researchers, government institutions, and commercial customers in areas such as human genetics, agricultural genomics, microbiology, and translational research.

The company’s primary revenue drivers are the sale of sequencing instruments, recurring consumables, and associated services. Pacific Biosciences is best known for its Single Molecule, Real-Time (SMRT) sequencing technology, which is differentiated by its ability to generate long, highly accurate reads. Founded in 2004, the company evolved from a research-focused startup into a publicly traded company following its 2010 initial public offering, with its strategy increasingly centered on scalable platforms and recurring consumables revenue.

Business Operations

Pacific Biosciences reports operating as a single reportable business segment, generating revenue through instrument sales, consumables, and service contracts tied to its sequencing platforms. Its core product lines include SMRT Long-Read Sequencing Systems such as the Sequel IIe System and the Revio System, as well as short-read sequencing through the Onso System, which originated from the acquisition of Omniome, Inc. These platforms are supported by proprietary chemistry, software, and bioinformatics tools.

Operations span domestic and international markets, with manufacturing, research and development, and commercial activities managed centrally. The company controls its core sequencing technologies and chemistry in-house while maintaining selected strategic collaborations with research institutions and commercial partners. Aside from Omniome, Inc., Pacific Biosciences’ corporate structure primarily consists of wholly owned subsidiaries supporting global sales and distribution.

Strategic Position & Investments

The company’s strategic direction is focused on expanding adoption of long-read sequencing by improving throughput, cost efficiency, and accuracy while broadening applications into clinical research and population-scale genomics. A key growth initiative has been the commercialization of the Revio System, designed for high-throughput sequencing at a lower cost per genome, and the expansion of short-read capabilities via the Onso System to complement its long-read offerings.

Pacific Biosciences’ most notable acquisition in recent years was Omniome, Inc., which provided short-read sequencing technology and expanded the company’s addressable market. The company continues to invest heavily in research and development to advance sequencing chemistry, software, and sample preparation. While the company has historically attracted strategic interest from larger industry participants, including prior equity investment from Roche, no material joint ventures currently represent a core pillar of its strategy based on available public disclosures.

Geographic Footprint

Pacific Biosciences is headquartered in Menlo Park, California, and maintains a global commercial and support presence across North America, Europe, and Asia-Pacific. The company serves customers in major research markets including the United States, Western Europe, China, and Japan, supported by regional sales, service, and application science teams.

International operations are primarily focused on sales, customer support, and distribution rather than manufacturing. The company’s global footprint reflects the concentration of genomic research funding and sequencing demand, with growing adoption in international population genomics and agricultural research initiatives.

Leadership & Governance

Pacific Biosciences was founded by scientists including Jonas Korlach and Stephen Turner, whose work helped establish the technical foundation of SMRT sequencing. The current leadership team emphasizes scientific rigor, platform scalability, and long-term technology leadership in genomics.

Key executives include:

• Christian Henry – President and Chief Executive Officer
• Susan Kim – Chief Financial Officer
• Jonas Korlach – Chief Technology Officer
• David Miller – Vice President, Global Commercial Operations

Management’s stated strategic vision centers on making high-fidelity sequencing broadly accessible while maintaining technological differentiation through continued innovation.